{"id":"methscopolamine","rwe":[],"_fda":{"id":"2ee941f2-7d8c-dd6e-e063-6394a90a0db9","set_id":"14c0c030-e96d-4a5e-95ff-02dd78a46be3","openfda":{"unii":["RTN51LK7WL"],"route":["ORAL"],"rxcui":["314088","403914"],"spl_id":["2ee941f2-7d8c-dd6e-e063-6394a90a0db9"],"brand_name":["METHSCOPOLAMINE BROMIDE"],"spl_set_id":["14c0c030-e96d-4a5e-95ff-02dd78a46be3"],"package_ndc":["72319-029-04","72319-029-06","72319-030-02","72319-030-06"],"product_ndc":["72319-029","72319-030"],"generic_name":["METHSCOPOLAMINE BROMIDE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["METHSCOPOLAMINE BROMIDE"],"manufacturer_name":["i3 Pharmaceuticals, LLC"],"application_number":["ANDA216786"],"is_original_packager":[true]},"version":"3","warnings":["WARNINGS In the presence of high environmental temperature, heat prostration (fever and heat stroke due to decreased sweating) can occur with drug use. Diarrhea may be an early symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy. In this instance treatment with this drug would be inappropriate and possibly harmful. Methscopolamine bromide may produce drowsiness or blurred vision. The patient should be cautioned regarding activities requiring mental alertness such as operating a motor vehicle or other machinery or performing hazardous work while taking this drug. With overdosage, a curare-like action may occur, i.e., neuromuscular blockade leading to muscular weakness and possible paralysis."],"pregnancy":["6. Pregnancy Teratogenic effects Animal reproduction studies have not been conducted with methscopolamine bromide. It is also not known whether methscopolamine bromide can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Methscopolamine bromide should be given to a pregnant woman only if clearly needed."],"overdosage":["OVERDOSAGE The symptoms of overdosage with Methscopolamine Bromide Tablets, 2.5 mg and 5 mg progress from intensification of the usual side effects to CNS disturbances (from restlessness and excitement to psychotic behavior), circulatory changes (flushing, fall in blood pressure, circulatory failure), respiratory failure, paralysis, and coma. Measures to be taken are (1) induction of emesis and (2) injection of physostigmine 0.5 to 2 mg intravenously, and repeated as necessary up to a total of 5 mg. Fever may be treated symptomatically (alcohol sponging, ice packs). Excitement of a degree which demands attention may be managed with sodium thiopental 2% solution given slowly intravenously or chloral hydrate (100 to 200 mL of a 2% solution) by rectal infusion. In the event of progression of the curare-like effect to paralysis of the respiratory muscles, artificial respiration should be instituted and maintained until effective respiratory action returns. The oral LD 50 in rats is 1,352 to 2,617 mg/kg. No data is available on the dialyzability of methscopolamine bromide."],"references":["REFERENCES 1.Gilman A, Gilman AB, Goodman LA, eds. The Pharmacological Basis of Therapeutics . 6th ed. New York: MacMillan Publishing Company.1980. 2.American Hospital Formulary Service. American Society of Hospital Pharmacists. Bethesda, Maryland. 3.Domino EF, Corasen G. Central and Peripheral Effects of Muscarinic Cholinergic Blocking Agents in Man. Anesthesiology 1967;28:568-574. 4.Mogensen L, Orinius E. Arrhythmic Complications after Parasympathetic Treatment of Bradyarrhythmias in a Coronary Care Unit. Acta Med Scand 1971; 190:495-498. 5.Neeld JB Jr., et al. Cardiac Rate and Rhythm Changes with Atropine and Methscopolamine. Clin Pharmacol Ther 1975;17(3):290-295. Rx Only Call your doctor for medical advice about side effects. You may report side effects to FDA at 1- 800-FDA-1088 Distributed By: i3 Pharmaceuticals, LLC 200 Park Avenue, Warminster, PA 18974 OS030-00 REV.0924 Rev. 09/24"],"description":["DESCRIPTION Methscopolamine Bromide Tablets, USP 2.5 mg and 5 mg contain methscopolamine bromide USP, an anticholinergic, which occurs as white crystals, or as a white odorless crystalline powder. Methscopolamine bromide melts at about 225°C with decomposition. The drug is freely soluble in water, slightly soluble in alcohol, and insoluble in acetone and in chloroform. The chemical name for methscopolamine bromide is 3-Oxa-9-azoniatricyclo [3.3.1.0 2,4 ]nonane, 7-(3-hydroxy-1-oxo-2-phenylpropoxy)-9, 9-dimethyl-, bromide, [7(s)-(1α, 2β, 4β, 5α, 7β)]- and the molecular weight is 398.30. The structural formula is represented below: Methscopolamine Bromide Tablets, USP 2.5 mg for oral administration contain 2.5 mg of methscopolamine bromide USP. Methscopolamine Bromide Tablets, USP 5 mg for oral administration contain 5 mg of methscopolamine bromide USP. Inactive ingredients: microcrystalline cellulose NF, pregelatinized starch NF, colloidal silicon dioxide NF, magnesium stearate NF. Contains no lactose. FDA approved impurity specifications differs from the USP. methscopolamine-structure"],"precautions":["PRECAUTIONS 1. General precautions Use Methscopolamine Bromide Tablets, 2.5 mg and 5 mg with caution in the elderly and in all patients with: autonomic neuropathy; hepatic or renal disease; or ulcerative colitis –large doses may suppress intestinal motility to the point of producing a paralytic ileus and for this reason precipitate or aggravate \"toxic megacolon,\" a serious complication of the disease. The drug also should be used with caution in patients having hyperthyroidism, coronary heart disease, congestive heart failure, tachyarrhythmia, tachycardia, hypertension, or prostatic hypertrophy. 2. Information for patient See statement under WARNINGS . 3. Laboratory tests Progress of the peptic ulcer under treatment should be followed by upper gastrointestinal contrast radiology or endoscopy to insure healing. Stool tests for occult blood and blood hemoglobin or hematocrit values should be followed to rule out bleeding from the ulcer. 4. Drug interactions Additive anticholinergic effects may result from concomitant use with antipsychotics, tricyclic antidepressants, and other drugs with anticholinergic effects. Concomitant administration with antacids may interfere with the absorption of methscopolamine bromide. 5. Carcinogenesis, mutagenesis, impairment of fertility No long-term studies in animals have been performed to evaluate carcinogenic potential. 6. Pregnancy Teratogenic effects Animal reproduction studies have not been conducted with methscopolamine bromide. It is also not known whether methscopolamine bromide can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Methscopolamine bromide should be given to a pregnant woman only if clearly needed. 7. Nursing mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when methscopolamine bromide is administered to a nursing woman. Anticholinergic drugs may suppress lactation. 8. Pediatric use Safety and efficacy in children have not been established."],"how_supplied":["HOW SUPPLIED Methscopolamine Bromide Tablets, USP 2.5 mg are available as white to off-white, round shaped biconvex tablets debossed \"S15\" on one side of the tablet and plain on the other side, in the following package size: Bottles of 100 (NDC 72319-029-04) Bottles of 1000 (NDC 72319-029-06) Methscopolamine Bromide Tablets, USP 5 mg are available as white to off-white, oval shaped biconvex tablets, debossed \"S16\" on one side of the tablet and plain on the other side, in the following package size: Bottles of 60 (NDC 72319-030-02) Bottles of 1000 (NDC 72319-030-06) Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Dispense in a tight, light- resistant container. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN."],"pediatric_use":["8. Pediatric use Safety and efficacy in children have not been established."],"effective_time":"20250224","nursing_mothers":["7. Nursing mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when methscopolamine bromide is administered to a nursing woman. Anticholinergic drugs may suppress lactation."],"laboratory_tests":["3. Laboratory tests Progress of the peptic ulcer under treatment should be followed by upper gastrointestinal contrast radiology or endoscopy to insure healing. Stool tests for occult blood and blood hemoglobin or hematocrit values should be followed to rule out bleeding from the ulcer."],"adverse_reactions":["ADVERSE REACTIONS The following adverse reactions have been observed, but there is not enough data to support an estimate of frequency. Cardiovascular : Tachycardia, palpitation. Allergic : Severe allergic reaction or drug idiosyncrasies including anaphylaxis. CNS : Headaches, nervousness, mental confusion, drowsiness, dizziness. Special Senses : Blurred vision, dilation of the pupil, cycloplegia, increased ocular tension, loss of taste. Renal : Urinary hesitancy and retention. Gastrointestinal : Nausea, vomiting, constipation, bloated feeling. Dermatologic : Decreased sweating, urticaria and other dermal manifestations. Miscellaneous : Xerostomia, weakness, insomnia, impotence, suppression of lactation."],"contraindications":["CONTRAINDICATIONS Glaucoma; obstructive uropathy (e.g., bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (e.g., pyloroduodenal stenosis); paralytic ileus; intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis. Methscopolamine Bromide Tablets, 2.5 mg and 5 mg is contraindicated in patients who are hypersensitive to methscopolamine bromide or related drugs."],"drug_interactions":["4. Drug interactions Additive anticholinergic effects may result from concomitant use with antipsychotics, tricyclic antidepressants, and other drugs with anticholinergic effects. Concomitant administration with antacids may interfere with the absorption of methscopolamine bromide."],"general_precautions":["1. General precautions Use Methscopolamine Bromide Tablets, 2.5 mg and 5 mg with caution in the elderly and in all patients with: autonomic neuropathy; hepatic or renal disease; or ulcerative colitis –large doses may suppress intestinal motility to the point of producing a paralytic ileus and for this reason precipitate or aggravate \"toxic megacolon,\" a serious complication of the disease. The drug also should be used with caution in patients having hyperthyroidism, coronary heart disease, congestive heart failure, tachyarrhythmia, tachycardia, hypertension, or prostatic hypertrophy."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Methscopolamine bromide is an anticholinergic agent which possesses most of the pharmacologic actions of that drug class. These include reduction in volume and total acid content of gastric secretion, inhibition of gastrointestinal motility, inhibition of salivary excretion, dilation of the pupil and inhibition of accommodation with resulting blurring of vision. Large doses may result in tachycardia."],"indications_and_usage":["INDICATIONS AND USAGE Adjunctive therapy for the treatment of peptic ulcer. METHSCOPOLAMINE BROMIDE HAS NOT BEEN SHOWN TO BE EFFECTIVE IN CONTRIBUTING TO THE HEALING OF PEPTIC ULCER, DECREASING THE RATE OF RECURRENCE OR PREVENTING COMPLICATIONS."],"information_for_patients":["2. Information for patient See statement under WARNINGS ."],"spl_unclassified_section":["PHARMACOKINETICS Methscopolamine bromide is a quaternary ammonium derivative of scopolamine. As a class, these agents are poorly and unreliably absorbed. 1,2 Total absorption of quaternary ammonium derivatives of the alkaloids is 10 to 25%. Rate of absorption is not available. Quaternary ammonium salts have limited absorption from intact skin, and conjunctival penetration is poor. 1 Little is known of the fate and excretion of most of these agents. 1 Following oral administration, drug effects appear in about one hour and persist for 4 to 6 hours. 2 Methscopolamine bromide has limited ability to cross the blood-brain barrier. 3,4,5 The drug is excreted primarily in the urine and bile, or as unabsorbed drug in feces. 2 There is no data on the presence of methscopolamine in breast milk; traces of atropine have been found after administration of atropine. 1"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION The average dosage of Methscopolamine Bromide Tablets is 2.5 mg one-half hour before meals and 2.5 to 5 mg at bedtime. A starting dose of 12.5 mg daily will be clinically effective in most patients without the production of appreciable side effects. If the patient is experiencing symptoms such as severe abdominal pain or cramping which demand prompt relief, the drug may be started on a daily dosage of 20 mg, administered in doses of 5 mg one- half hour before meals and at bedtime. If very unpleasant side effects develop promptly, the daily dosage should be reduced. If neither symptomatic relief nor side effects appear, the daily dosage may be increased. Some patients have tolerated 30 mg daily with no unpleasant reactions. Patients whose dosage has been reduced to eliminate or modify side effects often continue to show adequate response both subjectively in relief of symptoms and objectively as measured by antisecretory effects. The ultimate aim of therapy is to arrive at a dosage which provides maximal clinical effectiveness with a minimum of unpleasant side effects. Many patients report no side effects on a dosage which gives complete relief of symptoms. On the other hand, some patients have reported severe side effects without appreciable symptomatic relief. Such patients must be considered unsuited for this therapy. Usually they have been or will prove to be similarly intolerant to other anticholinergic drugs. If methscopolamine bromide is to be used in a patient who gives a history of such intolerance, it should be started at a low dosage."],"drug_abuse_and_dependence":["DRUG ABUSE AND DEPENDENCE Not Applicable."],"spl_product_data_elements":["METHSCOPOLAMINE BROMIDE methscopolamine bromide CELLULOSE, MICROCRYSTALLINE SILICON DIOXIDE MAGNESIUM STEARATE STARCH, CORN METHSCOPOLAMINE BROMIDE METHSCOPOLAMINE S15 white to off-white METHSCOPOLAMINE BROMIDE methscopolamine bromide CELLULOSE, MICROCRYSTALLINE SILICON DIOXIDE MAGNESIUM STEARATE STARCH, CORN METHSCOPOLAMINE BROMIDE METHSCOPOLAMINE white to off-white S16"],"package_label_principal_display_panel":["PACKAGE LABEL.PRINCIPAL DISPLAY PANEL methscopolamine-i3-2-5mg-100 methscopolamine-i3-2-5mg-1000 methscopolamine-i3-5mg-60 methscopolamine-i3-5mg-1000"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["5. Carcinogenesis, mutagenesis, impairment of fertility No long-term studies in animals have been performed to evaluate carcinogenic potential."]},"tags":[{"label":"Anticholinergic","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Muscarinic acetylcholine receptor M3","category":"target"},{"label":"CHRM3","category":"gene"},{"label":"CHRM4","category":"gene"},{"label":"CHRM1","category":"gene"},{"label":"A03BB03","category":"atc"},{"label":"Oral","category":"route"},{"label":"Tablet","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Mature","category":"status"},{"label":"Allergic rhinitis","category":"indication"},{"label":"Common cold","category":"indication"},{"label":"Cough","category":"indication"},{"label":"Irritable bowel syndrome","category":"indication"},{"label":"Nasal congestion","category":"indication"},{"label":"Nasal discharge","category":"indication"},{"label":"Fougera Pharms","category":"company"},{"label":"Approved 1950s","category":"decade"},{"label":"Parasympatholytics","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"15 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"15 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"15 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"14 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"14 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"13 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"10 reports"},{"date":"","signal":"FALL","source":"FDA FAERS","actionTaken":"9 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"8 reports"},{"date":"","signal":"ABDOMINAL PAIN","source":"FDA FAERS","actionTaken":"7 reports"}],"commonSideEffects":[{"effect":"Tachycardia","drugRate":"reported","severity":"unknown"},{"effect":"Palpitation","drugRate":"reported","severity":"unknown"},{"effect":"Anaphylaxis","drugRate":"reported","severity":"unknown"},{"effect":"Headaches","drugRate":"reported","severity":"unknown"},{"effect":"Nervousness","drugRate":"reported","severity":"unknown"},{"effect":"Mental confusion","drugRate":"reported","severity":"unknown"},{"effect":"Drowsiness","drugRate":"reported","severity":"unknown"},{"effect":"Dizziness","drugRate":"reported","severity":"unknown"},{"effect":"Blurred vision","drugRate":"reported","severity":"unknown"},{"effect":"Dilation of the pupil","drugRate":"reported","severity":"unknown"},{"effect":"Cycloplegia","drugRate":"reported","severity":"unknown"},{"effect":"Increased ocular tension","drugRate":"reported","severity":"unknown"},{"effect":"Loss of taste","drugRate":"reported","severity":"unknown"},{"effect":"Urinary hesitancy","drugRate":"reported","severity":"unknown"},{"effect":"Retention","drugRate":"reported","severity":"unknown"},{"effect":"Nausea","drugRate":"reported","severity":"unknown"},{"effect":"Vomiting","drugRate":"reported","severity":"unknown"},{"effect":"Constipation","drugRate":"reported","severity":"unknown"},{"effect":"Bloating","drugRate":"reported","severity":"unknown"},{"effect":"Decreased sweating","drugRate":"reported","severity":"unknown"},{"effect":"Urticaria","drugRate":"reported","severity":"unknown"},{"effect":"Xerostomia","drugRate":"reported","severity":"unknown"},{"effect":"Weakness","drugRate":"reported","severity":"unknown"},{"effect":"Insomnia","drugRate":"reported","severity":"unknown"},{"effect":"Impotence","drugRate":"reported","severity":"unknown"},{"effect":"Suppression of lactation","drugRate":"reported","severity":"unknown"}],"contraindications":["Achalasia of esophagus","Acidosis","Acute hepatitis","Acute pancreatitis","Alcohol intoxication","Angle-closure glaucoma","Arterial thrombosis","Arteriosclerotic vascular disease","Atony of colon","Autonomic dysreflexia","Benign prostatic hyperplasia","Bladder outflow obstruction","Bleeding","Bradycardia","Brain damage","Breastfeeding (mother)","Chronic heart failure","Chronic idiopathic constipation","Chronic lung disease","Chronic obstructive lung disease","Complete trisomy 21 syndrome","Coronary arteriosclerosis","Depressive disorder","Diabetes mellitus","Disease of liver"],"specialPopulations":{"Pregnancy":"Methscopolamine bromide should be given to pregnant woman only if clearly needed.","Paediatric use":"Safety and efficacy in children have not been established."}},"trials":[],"aliases":[],"company":"Fougera Pharms","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=METHSCOPOLAMINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:40:32.068670+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Methscopolamine","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T03:40:38.570992+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:40:37.162638+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T03:40:31.095172+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=METHSCOPOLAMINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:40:37.489109+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:40:30.439127+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:40:30.439161+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T03:40:38.981833+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Muscarinic acetylcholine receptor M1 antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:40:38.570953+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1354199/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:40:38.230778+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA216786","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:40:30.439165+00:00"}},"allNames":"methylscopolamine","offLabel":[],"synonyms":["methscopolamine","methylscopolamine","N-Methylhyoscine","N-Methylscopolamine","methscopolamine bromide","methscopolamine nitrate","methylscopolamine bromide"],"timeline":[{"date":"1953-04-09","type":"positive","source":"DrugCentral","milestone":"FDA approval (Fougera Pharms)"}],"aiSummary":"Methylscopolamine, also known as Methscopolamine, is a small molecule anticholinergic drug developed by Fougera Pharms and approved by the FDA in 1953. It targets the muscarinic acetylcholine receptor M3 and is used to treat various conditions such as allergic rhinitis, common cold, cough, irritable bowel syndrome, nasal congestion, and vasomotor rhinitis. The drug is off-patent and has multiple generic manufacturers. Key safety considerations include its potential to cause dry mouth, blurred vision, and constipation. As an anticholinergic, it works by blocking the action of acetylcholine, a neurotransmitter that stimulates muscle contraction and gland secretion.","approvals":[{"date":"1953-04-09","orphan":false,"company":"FOUGERA PHARMS","regulator":"FDA"}],"brandName":"Methylscopolamine","ecosystem":[{"indication":"Allergic rhinitis","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"antazoline","slug":"antazoline","company":"Novartis"},{"name":"astemizole","slug":"astemizole","company":""}],"globalPrevalence":null},{"indication":"Common cold","otherDrugs":[{"name":"acetylsalicylic acid","slug":"acetylsalicylic-acid","company":"Endo Pharms"},{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"ammonium chloride","slug":"ammonium-chloride","company":"B Braun"},{"name":"azatadine","slug":"azatadine","company":""}],"globalPrevalence":null},{"indication":"Cough","otherDrugs":[{"name":"ammonium chloride","slug":"ammonium-chloride","company":"B Braun"},{"name":"benzocaine","slug":"benzocaine","company":""},{"name":"benzonatate","slug":"benzonatate","company":"Pfizer"},{"name":"bromazine","slug":"bromazine","company":"Forest Labs"}],"globalPrevalence":null},{"indication":"Irritable bowel syndrome","otherDrugs":[{"name":"chlordiazepoxide","slug":"chlordiazepoxide","company":"Valeant Pharm Intl"},{"name":"clidinium","slug":"clidinium","company":"Roche"},{"name":"dicycloverine","slug":"dicycloverine","company":"Forest Labs Inc"},{"name":"homatropine","slug":"homatropine","company":""}],"globalPrevalence":null},{"indication":"Nasal congestion","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"ammonium chloride","slug":"ammonium-chloride","company":"B Braun"},{"name":"antazoline","slug":"antazoline","company":"Novartis"}],"globalPrevalence":null},{"indication":"Nasal discharge","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"ammonium chloride","slug":"ammonium-chloride","company":"B Braun"},{"name":"antazoline","slug":"antazoline","company":"Novartis"}],"globalPrevalence":30000000},{"indication":"Vasomotor rhinitis","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"antazoline","slug":"antazoline","company":"Novartis"},{"name":"azatadine","slug":"azatadine","company":""},{"name":"azelastine","slug":"azelastine","company":"Meda Pharms"}],"globalPrevalence":null}],"mechanism":{"target":"Muscarinic acetylcholine receptor M3","novelty":"Follow-on","targets":[{"gene":"CHRM3","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M3","protein":"Muscarinic acetylcholine receptor M3"},{"gene":"CHRM4","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M4","protein":"Muscarinic acetylcholine receptor M4"},{"gene":"CHRM1","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M1","protein":"Muscarinic acetylcholine receptor M1"},{"gene":"CHRM2","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M2","protein":"Muscarinic acetylcholine receptor M2"},{"gene":"CHRM5","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M5","protein":"Muscarinic acetylcholine receptor M5"}],"moaClass":"Cholinergic Antagonists","modality":"Small Molecule","drugClass":"Anticholinergic","explanation":"","oneSentence":"","technicalDetail":"Methylscopolamine is a competitive antagonist of the muscarinic acetylcholine receptor M3, which is involved in the regulation of smooth muscle contraction, gland secretion, and other physiological processes."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Methylscopolamine_bromide","title":"Methylscopolamine bromide","extract":"Methylscopolamine or methscopolamine, usually provided as the bromide or nitrate salt, is an oral medication used along with other medications to treat peptic ulcers by reducing stomach acid secretion. Proton pump inhibitors and antihistamine medications have made this use obsolete. It can also be used for stomach or intestinal spasms, to reduce salivation, and to treat motion sickness. Methscopolamine is also commonly used as a drying agent, to dry up post-nasal drip, in cold, irritable bowel syndrome and allergy medications"},"commercial":{"launchDate":"1953","_launchSource":"DrugCentral (FDA 1953-04-09, FOUGERA PHARMS)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1757","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=METHSCOPOLAMINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://en.wikipedia.org/wiki/Methylscopolamine_bromide","fields":["history","overview"],"source":"Wikipedia"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T14:22:57.250349","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:40:41.476184+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"methylhomatropine","drugSlug":"methylhomatropine","fdaApproval":"1943-03-23","relationship":"same-class"}],"genericName":"methscopolamine","indications":{"approved":[{"name":"Allergic rhinitis","source":"DrugCentral","snomedId":61582004,"regulator":"FDA"},{"name":"Common cold","source":"DrugCentral","snomedId":82272006,"regulator":"FDA"},{"name":"Cough","source":"DrugCentral","snomedId":49727002,"regulator":"FDA"},{"name":"Irritable bowel syndrome","source":"DrugCentral","snomedId":10743008,"regulator":"FDA"},{"name":"Nasal congestion","source":"DrugCentral","snomedId":68235000,"regulator":"FDA"},{"name":"Nasal discharge","source":"DrugCentral","snomedId":64531003,"regulator":"FDA","usPrevalence":null,"globalPrevalence":30000000,"prevalenceMethod":"curated","prevalenceSource":"Influenza Other Respir Viruses, 2023 (PMID:36824394)"},{"name":"Vasomotor rhinitis","source":"DrugCentral","snomedId":8229003,"regulator":"FDA"}],"offLabel":[{"name":"Rhinitis","source":"DrugCentral","drugName":"METHSCOPOLAMINE","evidenceCount":0,"evidenceLevel":"emerging"},{"name":"Seasonal allergic rhinitis","source":"DrugCentral","drugName":"METHSCOPOLAMINE","evidenceCount":0,"evidenceLevel":"emerging"}],"pipeline":[]},"drugCategory":"mature","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"methylhomatropine","brandName":"methylhomatropine","genericName":"methylhomatropine","approvalYear":"1943","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Tablet","formulations":[{"form":"TABLET","route":"ORAL","productName":"METHSCOPOLAMINE BROMIDE"},{"form":"TABLET","route":"ORAL","productName":"Methscopolamine Bromide"},{"form":"TABLET","route":"ORAL","productName":"Pamine"},{"form":"TABLET","route":"ORAL","productName":"Pamine Forte"},{"form":"TABLET","route":"ORAL","productName":"Methscopolamine Bromide"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000147918","MMSL":"5082","NDDF":"001720","UNII":"VDR09VTQ8U","VUID":"4019830","CHEBI":"CHEBI:135361","VANDF":"4018075","RXNORM":"56092","UMLSCUI":"C0301374","chemblId":"CHEMBL1354199","ChEMBL_ID":"CHEMBL1201268","DRUGBANK_ID":"DB11315","PDB_CHEM_ID":" 3C0","PUBCHEM_CID":"71183","SNOMEDCT_US":"28415002","IUPHAR_LIGAND_ID":"316","SECONDARY_CAS_RN":"155-41-9","MESH_DESCRIPTOR_UI":"D019832"},"formularyStatus":[],"originalProduct":{"form":"TABLET","route":"ORAL","company":"PharmaDerm a division of Fougera Pharmaceuticals Inc.","brandName":"Pamine","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1953-","companyName":"Fougera Pharms","relationship":"Original Developer"}],"publicationCount":129,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"A03BB03","allCodes":["A03BB03","A03CB01","S01FA03"]},"biosimilarFilings":[],"originalDeveloper":"Fougera Pharms","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":5,"_genericFilersChecked":true,"genericManufacturerList":["Breckenridge Pharm","Chartwell Rx","Ne Rx Pharma","Pvt Form","Unichem"],"status":"approved","companyName":"Fougera Pharms","companyId":"fougera-pharms","modality":"Small molecule","firstApprovalDate":"1953","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1953-04-09T00:00:00.000Z","mah":"FOUGERA PHARMS","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2011-12-06T00:00:00.000Z","mah":"BRECKENRIDGE PHARM","brand_name_local":null,"application_number":"ANDA040642"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2012-09-24T00:00:00.000Z","mah":"UNICHEM","brand_name_local":null,"application_number":"ANDA200602"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-02-01T00:00:00.000Z","mah":"NE RX PHARMA","brand_name_local":null,"application_number":"ANDA216786"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:40:41.476184+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":false,"score":2}}